European Archives - Page 956 of 1108 - European Medical Journal

EMJ

CHD1 Depletion Sensitises Prostate Cancer Cells to Chemotherapy Drugs

DEPLETING prostate cancer cell lines of a DNA-binding protein makes them hypersensitive to chemotherapeutic drugs, suggesting a possible opening for…

EMJ

Pelvic Floor Disorders: Female Triathletes Running to Incontinence

DEVOTED female triathletes have been identified as having a high rate of pelvic floor disorders.

EFIC Symposium: Strong Opioids Suitable for Elderly Patients – Weight Loss Reduces Joint Pain

Dubrovnik, September 24, 2016 – Elderly patients with chronic musculoskeletal pain often receive inadequate medical treatment. A recent Polish study…

EMJ

Cell Diversity in Barrett’s Oesophagus Patients Good Predictor of Cancer Risk

The genetic diversity measured between the cells affected by Barrett’s oesophagus has been found to be a good predictor of which patients are at a high…

EMJ

Nanotechnology Applied to Ginger Offers Novel Treatment for Bowel Disease

NANOPARTICLES derived from ginger have been used to produce a beneficial effect in the treatment of inflammatory bowel disease (IBD), offering a novel…

EFIC Symposium: New Therapeutic Strategies to Combat Joint Pain

Dubrovnik, September 23, 2016 – Joint pain continues to be one of the main reasons for persisting disablement. One explanation, among others, is that…

EFIC Symposium: Chronic Pain Following Joint Surgery – Experts Call for New Approaches

Dubrovnik, September 22, 2016 – Many patients are disappointed and dissatisfied when they find they are still experiencing pain in the months and years…

EFIC Symposium: Myths and Facts About Joint Pain

Dubrovnik, September 21, 2016 – A lot of incorrect assumptions about joint pain are in circulation. “The sometimes overly pessimistic misconceptions can…

Merck Presents New Data on the Safety and Durable Efficacy of Cladribine Tablets and Advantages of Early Treatment with Rebif® at the 2016 ECTRIMS Congress

Germany, September 12, 2016 – Merck, a leading science and technology company, today announced key symposia and more than 30 presentations of clinical…

Janssen Receives CHMP Positive Opinion for STELARA® (Ustekinumab) Recommending Approval for the Treatment of Moderately to Severely Active Crohn’s Disease in the European Union

Belgium, September 16, 2016 – Janssen-Cilag International NV (“Janssen”) announced today that the Committee for Medicinal Products for Human Use (CHMP)…